{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesion","groups":[{"description":"Patients receive SB-715992 IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.\n\nispinesib: Given IV\n\nlaboratory biomarker analysis: Correlative studies\n\npharmacological study: Correlative studies","id":"OG000","title":"Treatment (Ispinesib)"}],"paramType":"NUMBER","populationDescription":"20 eligible patients were analyzed","reportingStatus":"POSTED","timeFrame":"Up to 18 months","title":"Antitumor Activity of SB-715992 Using Objective Response Rates (Partial and Complete Responses)","type":"PRIMARY","unitOfMeasure":"participants"}